Stevan Vasich

Stevan Vasich serves as a key procurement lead within the Department of Veterans Affairs, supporting Nac Pharmaceuticals (36E797) in securing essential pharmaceuticals for enrolled veterans nationwide. He manages the full lifecycle of acquisitions for prescription medications, including chronic disease therapeutics, acute care formulations, and specialty drug products, ensuring compliance with federal procurement regulations and VA healthcare delivery standards. His work directly supports the agency’s mission to maintain uninterrupted access to high-priority pharmaceuticals through strategic sourcing and supply chain resilience initiatives. Vasich maintains consistent contracting relationships with leading pharmaceutical manufacturers and distributors, including Avkare LLC, Dr. Reddy’s Laboratories, Inc., Progenics Pharmaceuticals Inc., Golden State Medical Supply, Inc., and Seqirus USA Inc. These partnerships reflect a preference for established, FDA-compliant suppliers capable of meeting stringent quality, regulatory, and distribution requirements. His procurement approach emphasizes reliability, batch consistency, and regulatory adherence over cost alone, fostering long-term vendor collaborations grounded in performance accountability and supply continuity. His acquisition portfolio reflects no set-aside preferences, with 100% of awards issued under full and open competition. This indicates a deliberate focus on maximizing access to the broadest possible pool of qualified manufacturers, prioritizing product availability, regulatory compliance, and supply chain stability over socioeconomic targeting. While small business participation is not formally incentivized, all vendors are evaluated on technical capability, regulatory history, and capacity to meet VA’s mission-critical needs. Vasich’s primary procurement focus lies in NAICS 325412 (Pharmaceutical Preparation Manufacturing), which accounts for 82.3% of his activity, underscoring deep expertise in sourcing finished dosage forms, sterile injectables, and oral solid medications. The remaining 17.6% involves NAICS 339112 (Surgical and Medical Instrument Manufacturing), reflecting occasional procurement of specialized drug delivery devices. His domain expertise centers on complex pharmaceutical supply chains, GMP compliance, and cold-chain logistics for sensitive biologics and controlled substances.